Evidence map›Paper›PMID 35914225›Full record

ArticleBlood advances2022

C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy.

Hridaya Shah, Hang Chen, Xiang-Zuo Pan, Ara Metjian, Robert A Brodsky, Evan M Braunstein, Shruti Chaturvedi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hridaya ShahZanvyl Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD.
Hang ChenDivision of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.
Xiang-Zuo PanDivision of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.
Ara MetjianDivision of Hematology and Oncology, Department of Medicine, University of Colorado School of Medicine, Anschutz, CO.ORCID 0000-0001-9890-8639
Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.ORCID 0000-0001-5741-1255
Evan M BraunsteinDivision of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.
Shruti ChaturvediDivision of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.

Funding

ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic PurpuraK99HL150594 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHATURVEDI, SHRUTI · 2020 to 2023
$907k
NHLBI NIH HHS K99 HL150594
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsNeoplasmsThrombotic MicroangiopathiesHumansAntineoplastic Agents

Identifiers

PMID35914225
PMCPMC9713277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.